<DOC>
	<DOCNO>NCT01971684</DOCNO>
	<brief_summary>The purpose study understand physician treatment decision select specific second line treatment pediatric ITP determine effectiveness different second line ITP treatment . Eligible patient age 1-18 year start new second line treatment ITP , define treatment IVIG , steroid , anti-D globulin , aminocaproic acid . Enrolled patient remain study approximately one year .</brief_summary>
	<brief_title>ICON1 : Treatment Decisions Outcomes Pediatric Refractory ITP</brief_title>
	<detailed_description>The purpose observational study model factor determine physician treatment decision select specific second line agent pediatric ITP determine comparative effectiveness second line ITP treatment bleed measure , platelet count , patient report outcome measure . This prospective observational , longitudinal , multicenter cohort study aim collect routine clinical care data , quality life information patient , decision making data clinician enrollment regular clinical interval least one year . The primary secondary objective follow : Primary Objectives : 1 . To model factor determine physician treatment decision select specific second line agent pediatric ITP . 2 . To assess patient report outcomes relation specific second line pediatric ITP therapy . 3 . To determine comparative effectiveness second line ITP treatment term bleed platelet count . Secondary Objectives : 1 . To describe phenotypic variation among patient refractory ITP ; 2 . To assess side effect complication relate specific treatment refractory ITP ; 3 . To describe monitoring follow practice among pediatric hematologist second line agent ; 4 . To weight factor physician use decide treat pediatric ITP patient second line agent ; 5 . To determine whether physician perception patient quality life correlate patient derive quality life measure ; 6 . To measure correlation ITP Bleeding Scale Bleeding Assessment Tool refractory pediatric ITP patient .</detailed_description>
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic , Idiopathic</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<criteria>Immune Thrombocytopenia Evans Syndrome Ages &gt; 12 month &lt; 18 year Starting new second line therapy define therapy except IVIG , steroid , antiD globulin , aminocaproic acid Starting single agent/monotherapy Evans Syndrome history current evidence autoimmune hemolytic anemia Unwillingness follow 1 year Physician provide care unwilling participate Patient start multiple second line agent simultaneously</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>ITP</keyword>
	<keyword>idiopathic thrombocytopenic purpura</keyword>
	<keyword>bleed score</keyword>
	<keyword>platelet count</keyword>
	<keyword>health-related quality life</keyword>
	<keyword>HRQL</keyword>
	<keyword>Purpura</keyword>
	<keyword>Purpura , Thrombocytopenic</keyword>
	<keyword>Purpura , Thrombocytopenic , Idiopathic</keyword>
	<keyword>Blood Coagulation Disorders</keyword>
	<keyword>Hematologic Diseases</keyword>
	<keyword>Hemorrhage</keyword>
	<keyword>Skin Manifestations</keyword>
	<keyword>Thrombocytopenia</keyword>
	<keyword>Blood Platelet Disorders</keyword>
	<keyword>Immune System Diseases</keyword>
	<keyword>Hemorrhagic Disorders</keyword>
	<keyword>Autoimmune Diseases</keyword>
	<keyword>Therapeutic Uses</keyword>
</DOC>